Zealand Pharma gets positive CHMP opinion for Zeydovio in short bowel syndrome
Zealand Pharma says the CHMP has issued a positive opinion for Zeydovio (glepaglutide) for treating short bowel syndrome.
Press release No. 16 / 2026 states that Zealand Pharma has received a positive CHMP opinion for Zeydovio™ (glepaglutide) for the treatment of short bowel syndrome. The company is based in Copenhagen, Denmark, and the release is dated September 18, 2026. Zealand Pharma A/S is listed on NASDAQ:ZEAL and has CVR-no.
20045078.